<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193293</url>
  </required_header>
  <id_info>
    <org_study_id>VS-0145-130</org_study_id>
    <nct_id>NCT04193293</nct_id>
  </id_info>
  <brief_title>A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer</brief_title>
  <official_title>A Phase 1b/2 Study of Duvelisib in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and preliminary efficacy of duvelisib in combination with&#xD;
      pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell&#xD;
      carcinoma (HNSCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate&#xD;
      safety and tolerability and preliminary efficacy of duvelisib in combination with&#xD;
      pembrolizumab in subjects with R/M HNSCC who are eligible for pembrolizumab monotherapy based&#xD;
      on the current pembrolizumab prescribing information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Patient Recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">November 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Number of participants with dose-limiting toxicities (DLTs)</measure>
    <time_frame>4 weeks or 28 days</time_frame>
    <description>Number of participants with dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Number of participants with treatment-emergent adverse events.</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.as a measure of safety and tolerability of duvelisib in combination with pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1 &amp; 2 Combined Primary Objective: Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of subjects achieving complete response (CR) or partial response (PR) according to RECIST v 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Unique Secondary Objective: ORR</measure>
    <time_frame>Until documented PD, unacceptable toxicity, discontinuation criteria are met, withdrawal, or death. Up to 2 years.</time_frame>
    <description>Proportion of subjects achieving complete CR or PR according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 &amp; 2 Combined Secondary Objective: Duration of response (DOR)</measure>
    <time_frame>From first response until documented PD. Up to 2 years.</time_frame>
    <description>Time from response ≥ PR to documented disease progression according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 &amp; 2 Combined Secondary Objective: Progression-free survival (PFS)</measure>
    <time_frame>From start of treatment until documented PD or death. Assessed up to 2.5 years.</time_frame>
    <description>Time from start of treatment to documented disease progression according to RECIST v 1.1, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 &amp; 2 Combined Secondary Objective: Overall survival (OS)</measure>
    <time_frame>From start of treatment until death. Assessed up to 2.5 years.</time_frame>
    <description>Time from start of treatment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 &amp; 2 Combined Secondary Objective: Maximum observed concentration [Cmax]</measure>
    <time_frame>Up to 5 cycles (46 weeks).</time_frame>
    <description>PK parameters for duvelisib (and metabolite IPI-656) will be determined using bioanalytical data and Population PK (POPPK) modeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 &amp; 2 Combined Secondary Objective: Area under the curve [AUC]</measure>
    <time_frame>Up to 5 cycles (46 weeks).</time_frame>
    <description>PK parameters for duvelisib (and metabolite IPI-656) will be determined using bioanalytical data and POPPK modeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 &amp; 2: Number of participants with treatment-emergent adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Duvelisib BID + Pembrolizumab q3w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Duvelisib BID for 1 week followed by combination therapy with duvelisib BID + pembrolizumab q3w. (Cycle 1 will be 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib. Subsequent cycles will be 3 weeks .)&#xD;
Stage 2: Duvelisib BID + pembrolizumab q3w in 3 week cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duvelisib</intervention_name>
    <description>PI3K Inhibitor</description>
    <arm_group_label>Duvelisib BID + Pembrolizumab q3w</arm_group_label>
    <other_name>VS-0145</other_name>
    <other_name>Copiktra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Immunotherapy (PD-1 inhibitor)</description>
    <arm_group_label>Duvelisib BID + Pembrolizumab q3w</arm_group_label>
    <other_name>PD-1 inhibitor</other_name>
    <other_name>anti-PD-1</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years, ECOG performance status ≤ 1&#xD;
&#xD;
          -  Histologically or cytologically-confirmed diagnosis of recurrent or metastatic head&#xD;
             and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or&#xD;
             larynx that is considered incurable by local therapies&#xD;
&#xD;
          -  Eligible for pembrolizumab monotherapy based on the current prescribing information&#xD;
             for pembrolizumab (Keytruda 2019)&#xD;
&#xD;
          -  Must have had 0 to 2 prior therapies for R/M HNSCC.&#xD;
&#xD;
          -  At least 1 measurable lesion (which has not been previously irradiated) according to&#xD;
             RECIST v 1.1&#xD;
&#xD;
          -  For stage 1 only: Must have at least 1 other lesion that can be biopsied and willing&#xD;
             to undergo a pretreatment and on-treatment biopsy of the available tumor lesion&#xD;
&#xD;
          -  For stage 1 only: Must be willing to undergo a pretreatment and on-treatment biopsy of&#xD;
             the available tumor lesion&#xD;
&#xD;
          -  Adequate organ function defined by the following laboratory parameters:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L&#xD;
&#xD;
          -  Platelet count ≥ 100 × 109/L&#xD;
&#xD;
          -  Hemoglobin level ≥ 9.0 g/dL&#xD;
&#xD;
          -  A serum creatinine level &lt; 1.5 mg/dL, or&#xD;
&#xD;
          -  Estimated creatinine clearance value ≥ 60 mL/min (as determined by the Cockcroft-Gault&#xD;
             method) for subjects with creatinine levels &gt; 1.5 × institutional upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Total bilirubin level ≤ 1.5 × ULN (exception: subjects with Gilbert's Syndrome may&#xD;
             have a bilirubin level &gt; 1.5 × ULN)&#xD;
&#xD;
          -  Aspartate aminotransaminase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and&#xD;
             alanine aminotransferase (ALT)/serum pyruvic transaminase (SGPT) levels ≤ 2.5 × ULN or&#xD;
             ≤ 5 × ULN in subjects with liver metastases&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) and activated partial&#xD;
             thromboplastin time (aPTT) ≤ 1.5 × ULN, unless subject is receiving anticoagulant&#xD;
             therapy in which case PT or aPTT must be within therapeutic range of intended use of&#xD;
             anticoagulants&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Previously treated with 3 or more systemic regimens given for recurrent and/or&#xD;
             metastatic disease&#xD;
&#xD;
          -  Received anticancer treatment, major surgery, or any investigational drug within 30&#xD;
             days or 5 half-lives, whichever is shorter, before the start of study intervention&#xD;
&#xD;
          -  Received radiation therapy within 14 days before the start of study intervention,&#xD;
             including, in addition (if necessary), the timeframe for resolution of any actual or&#xD;
             anticipated toxicities from such radiation; Palliative radiation is allowed if &gt; 7&#xD;
             days and any toxicity is ≤ Grade 1&#xD;
&#xD;
          -  Previous treatment with a PI3K, PD-1 or PD-L1 inhibitor&#xD;
&#xD;
          -  Have received organ or allogenic bone marrow or peripheral blood stem cell transplant&#xD;
&#xD;
          -  History of drug-induced colitis or drug-induced pneumonitis; history or concurrent&#xD;
             condition of interstitial lung disease of any severity and/or severely impaired lung&#xD;
             function; tuberculosis treatment within 2 years prior to the start of study&#xD;
             intervention; chronic liver disease or veno-occlusive disease/sinusoidal obstruction&#xD;
             syndrome&#xD;
&#xD;
          -  Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection; history of or&#xD;
             known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Ongoing treatment with chronic immunosuppressants or systemic steroids or treatment&#xD;
             for systemic bacterial, fungal, or viral infection&#xD;
&#xD;
          -  Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV),&#xD;
             or herpes zoster (VZV) at screening&#xD;
&#xD;
          -  Concurrent administration of medications or foods that are strong inhibitors or&#xD;
             inducers of cytochrome P450 3A (CYP3A). No prior use within 2 weeks before the start&#xD;
             of study intervention Received a live or live attenuated vaccine within 6 weeks of&#xD;
             first dose of duvelisib&#xD;
&#xD;
          -  Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV),&#xD;
             or herpes zoster (VZV) at screening&#xD;
&#xD;
          -  Any active gastrointestinal dysfunction interfering with the subject's ability to be&#xD;
             administered oral medications&#xD;
&#xD;
          -  Known active central nervous system metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  QT interval &gt; 500 ms (except for subjects with a right or left bundle branch block)&#xD;
&#xD;
          -  New York Heart Association Class III or IV congestive heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cohan, MD</last_name>
    <role>Study Director</role>
    <affiliation>SecuraBio Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma of the Head and Neck</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>PI3K-δ,γ</keyword>
  <keyword>PI3K Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

